James E. Bradner M.D. — President of Novartis Institutes for Biomedical Research at Novartis

Dr. James M. Bradner, also known as Jay, M.D., has been President of Novartis Institutes for BioMedical Research, Inc. at Novartis AG since March 1, 2016. Dr. Bradner is the Scientific Founder of Acetylon Pharmaceuticals, Inc. Dr. Bradner is the Founder of C4 Therapeutics, Inc. He is a Scientific Founder of Acetylon Pharmaceuticals, TetraLogic Research and Development Corporation and Tensha Therapeutics, Inc. He serves as Staff Physician at Dana Farber Cancer Institute. He serves as Physician-Scientist, Chemical Biology Group, Broad Institute; Associate Physician, Brigham and Women's Hospital; and Instructor of Medicine, Harvard Medical School. He leads a chemical biology group at the Broad Institute investigating cellular function of histone deacetylases and the role of autophagy in hematologic malignancies. His group applies forward and reverse chemical genetic platforms, high-content screening and small-molecule microarrays for ligands modulating autophagy. Dr. Bradner is Associate Director of the Center for the Science of Therapeutics (CSofT) at the Broad Institute where he has worked since 2004. He serves as an Assistant Professor of Medicine at Harvard Medical School. He was an Associate Professor at Harvard Medical School. He is the Scientific Founder of Syros Pharmaceuticals, Inc. He serves as a Director of Tensha Therapeutics, Inc. He serves as a Director of TetraLogic Research and Development Corporation. He serves as a Member of Scientific Advisory Board at Acetylon Pharmaceuticals, Inc. He served as a Member of the Supervisory Board at Qiagen NV since June 2015 until December 31, 2015. He served as a Director and Member of Scientific Advisory Board at Syros Pharmaceuticals since April 2013 until October 2015. He served as a Member of Scientific Advisory Board at Agios Pharmaceuticals, Inc., since November 24, 2008. Dr. Bradner has co-authored more than 130 scientific publications and 30 United States Patent applications. He is attending physician in the Department of Hematology-Oncology at the Dana-Farber Cancer Institute. Dr. Bradner received his AB in Biochemical Sciences from Harvard University in 1994, his M.D. from the University of Chicago in 1999 and his M.M.S. from Harvard Medical School.